Finding treatment weaknesses in synovial sarcoma cancer cells
Project 3: Identifying Targetable Epigenetic and Immuno-Oncologic Vulnerabilities in Synovial Sarcoma
This study is looking at a type of cancer called synovial sarcoma to find out how certain genetic changes might make it more vulnerable to new treatments, especially by combining special therapies that target genes with those that help the immune system fight the cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10848816 on NIH RePORTER |
What this research studies
This research focuses on synovial sarcoma, a type of cancer that may have unique vulnerabilities due to specific genetic changes. The team aims to identify these vulnerabilities by studying how certain proteins and genetic modifications affect cancer cell behavior. They will explore the potential for combining epigenetic therapies with immunotherapy to improve treatment outcomes. By analyzing cancer cells and their responses to different treatments, the research seeks to develop more effective strategies for managing this aggressive cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with synovial sarcoma, particularly those with advanced or metastatic disease.
Not a fit: Patients with other types of cancer or those without synovial sarcoma may not benefit from this specific research.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies that improve survival rates and quality of life for patients with synovial sarcoma.
How similar studies have performed: Previous research has shown promise in targeting epigenetic vulnerabilities in other cancers, suggesting potential success for this novel approach in synovial sarcoma.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Ladanyi, Marc — Sloan-Kettering Inst Can Research
- Study coordinator: Ladanyi, Marc
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.